Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
about
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideEribulin in Cancer TreatmentEribulin in the management of inoperable soft-tissue sarcoma: patient selection and survivalEfficacy of eribulin in breast cancer: a short report on the emerging new data.Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study.Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.Emerging therapies for breast cancerBrain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case SeriesEribulin for heavily pre-treated metastatic breast cancer patientsDetecting overall survival benefit derived from survival postprogression rather than progression-free survival.Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review.A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer.CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.In vivo imaging of eribulin-induced reoxygenation in advanced breast cancer patients: a comparison to bevacizumabPooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.Defining the optimal sequence for the systemic treatment of metastatic breast cancer.Eribulin long-term response and rechallenge: report of two clinical cases.Long-term treatment with eribulin in heavily pretreated women with metastatic breast cancer: a case series.ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study.Efficacy and safety of eribulin in taxane-refractory patients in the 'real world'.Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient.Benefit of eribulin in a patient with HER2(+) breast cancer who progressed after trastuzumab and lapatinib: a case report.Long response to eribulin in breast cancer: a case report.Eribulin in non-small cell lung cancer: challenges and potential strategies.Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice.Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579).Care of the Elderly Patient on Oral Oncolytics for Advanced Disease.Axonal Transport Impairment in Chemotherapy-Induced Peripheral NeuropathyPhosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells.Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study.Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies.Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer.Eribulin in advanced breast cancer: safety, efficacy and new perspectives.New agents for the management of resistant metastatic breast cancer.Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin.Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan.
P2860
Q26749476-047BA9F6-3467-4E22-88B2-75D1CC9E97B9Q26799328-B8C8BA33-BA51-4FD4-B1A4-6B947B6D488FQ28074125-A2BFD1DC-BD99-45C6-A764-D5AFC20EBC60Q31167441-BC0B8290-122E-44E8-96BB-93298758C029Q33426567-E1216288-0002-452F-BB79-B3CC24B163B3Q33584160-49BF89A7-7C18-4E77-A40B-BF351E9681E4Q33617949-57A86FD0-3108-4DD4-8FC3-FF5AEC121A95Q35647947-E1B8AB96-58FD-470E-89C6-3448832D9BA0Q35756426-8027B5F7-253A-42B4-A1B3-FD9D4A495CEEQ36173497-21E978C0-C10A-4B33-B891-BE0E1027C6D9Q36234055-A9FEA106-D56D-4D97-9E5D-39CEA12FE0F7Q36614786-30F9FD71-A10C-47DC-87D6-64DDFA876A5DQ36668951-9A82F1BA-086E-45F1-86CB-DB3B13F82260Q36742259-AFEFF3BD-14B1-4A55-B481-1C0CF090D5B4Q36964337-D9A95592-23E7-4885-99F2-755C75A0D8A9Q37123925-2CF37063-A28F-44D8-ADEE-BD6870CB8BCAQ37588645-26F94CA5-9F2F-43B5-8B76-2F535365C194Q38686613-567D9B76-25F2-4DD3-826C-C67A3F0C8ABBQ38686628-46C24E3A-B749-45D4-B7F3-D08F7D475A0CQ38692409-49DE7E5E-7807-4EC5-9CE1-8729CE765A12Q38741802-301D68FB-4E5B-478B-9BA4-7BB0724EA8BFQ38978439-5F0A7946-D363-46AB-B0C7-C2A396C1C0C9Q38978448-9631AC8B-B03F-421E-96D1-FFF4C884E5AAQ38978452-B6C6A630-7516-4138-BAFA-02558FAF2662Q39120142-9781196E-7E5B-4272-9F86-1F359EFFCDF5Q40120892-33F4ED30-9F21-4D0D-BC77-9F661A34C748Q41719274-77CC5F52-99B7-4D11-AC92-E308BDFC3681Q41961879-991FB399-F897-485F-B641-F180FEFC3386Q42361415-5CE9A1F2-A112-423B-9AC5-F758777899C7Q44174238-781EAD74-B530-42A9-8776-C60516F9E18BQ44969452-F9EB0661-398B-453E-BE8B-A21C3CFA9DC7Q45392298-68A524F8-EC32-456E-B891-C03E7156C1F2Q46592179-3CB82426-4518-4F51-80D7-22ACF7793670Q47794057-B15708C6-8A17-4A32-A8C7-39EEB4390C1FQ48240854-949E6720-DD47-44CB-A29B-8C6604B13201Q48305630-1696B4D4-EA13-46B9-814C-C5DA34E0E2D1Q49662817-81628169-463A-4260-B982-A046C694B59FQ49787954-020385CD-B0B4-4E0D-B394-F38655390243Q50045537-EBA014CA-5A22-4842-B7E9-A4FDAAE4753FQ52603297-3C70691D-23DF-4AE2-8CAE-3CCE74133AC4
P2860
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@ast
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en-gb
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@nl
type
label
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@ast
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en-gb
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@nl
prefLabel
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@ast
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en-gb
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@nl
P2093
P2860
P1476
Efficacy of eribulin in women ...... alysis of two phase 3 studies.
@en
P2093
Ahmad Awada
Chris Twelves
Martin Olivo
Peter A Kaufman
P2860
P2888
P304
P356
10.1007/S10549-014-3144-Y
P407
P577
2014-11-08T00:00:00Z
P5875
P6179
1002219105